Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Vancouver, Canada and Deerfield, Illinois, USA, February 19, 2007 -- Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) and its co-development partner Astellas Pharma US, Inc. today announced that the...
Read more about Cardiome and Astellas Announce Acceptance of NDA for Review
MELVILLE, N.Y.--(BUSINESS WIRE)--Jan. 29, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European...
Larger vial offers more convenient usage, less waste PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the availability of their antifungal agent MYCAMINE® (micafungin sodium)...
Read more about Astellas Pharma US, Inc. Announces Availability of MYCAMINE® 100mg Vial
Submission of additional indication supports Astellas' commitment to the Infectious Disease community PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today that, on December 21,...
MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 15, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee...
Rookie Driver J.J. Yeley to Drive VESIcare Car at Bass Pro Shop MBNA 500 Atlanta, GA (October 29, 2006) — It is estimated that 17 million men and women in the United States, especially those age...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has begun a Phase III clinical trial of Tarceva® (erlotinib) as a targeted...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 28, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Roche, its international partner for Tarceva® (erlotinib), received a negative...
Two Follow-Up Studies Indicate Better Renal Function for Patients with Chronic Graft Dysfunction Converted to Prograf ® BOSTON, July 25, 2006 – Research presented today at the World Transplant...
ATLANTA, Jun 06, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided a summary of data from studies involving the company's leading product, Tarceva® (erlotinib),...
Follow U.S. news
